Understanding the biological properties of AML LSCs, particularly their similarities and differences from normal CD34+CD38− hematopoietic stem cells (HSCs) and their heterogeneity and plasticity in individual patients is important for the development of therapies that can specifically eradicate these cells during the course of disease. The gene discussed is CD34; the disease is acute myeloid leukemia.